Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In HIV Research, A Race For The Cure Is Back On Track

This article was originally published in Start Up

Executive Summary

Hopes for a vaccine or cure for HIV/AIDS have been dashed before. But recent scientific advances and greater understanding of the limits of antiretroviral drugs have reignited optimism. Just don't expect VCs to get on board.

You may also be interested in...



Janssen Strives For Simplicity In HIV R&D, While Hunting For A Cure

HIV may be effectively treated and managed with available therapies, but there is still great unmet need for a functional cure and better prevention to stop the epidemic.

The A-List: The Trend-Shaping Series A Financings Of 2012

There’s still money for early-stage innovation despite worries to the contrary, but total dollars for Series A financings remain about one-third fewer than during the high years of the mid-2000s, and investor syndicates are mindful of making those dollars stretch as far as possible. For the 2012 A-List, our ninth, we’ve decided to ask a fundamental question as the life science venture world goes through economic upheaval: does “Series A” mean the same thing, or conjure the same connotations, as it did when the class of 2004 made the first A-List?

Novira Receives $23 Million To Develop New Antivirals

Previously supported by angels and seed-stage investors, the Philadelphia-area start-up has turned to 5AM Ventures and Canaan Partners for a Series A round that will support development of HBV and HIV drug candidates.

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel